E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10000614 |
E.1.2 | Term | Actinic keratosis |
E.1.2 | System Organ Class | 10040785 - Skin and subcutaneous tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary objective is to investigate whether local skin responses seen after Picato® can be treated with a topical glucocorticosteroid. Secondary objective is to investigate if the treatment efficacy is affected by it. It is the perspective of this study to be offer patients safe treatment of local skin responses after Picato® treatment while maintaining an effective eradication of the Actinic Keratoses. |
|
E.2.2 | Secondary objectives of the trial |
Evaluate if patient satisfaction as well as short and long term side effects (hyperpigmentation, hypopigmentation and scarring) are affected by the use of a topical glucocorticosteroid after Picato® treatment. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Age 18 or older • Two eligible areas of 25 cm2 containing 4-20 AK lesions in the face or two eligible areas of 25 cm2 containing 4-20 AK lesions in the scalp • Minimally four lesions in every area are Grade I or II (Grade I: Thin lesions, are better felt than seen, Grade II: Moderately thick, are easily seen and felt, Grade III Very thick and/or hyperkeratotik lesions) • Fertile women must document non-reactive urine pregnancy test at the day of inclusion • During the study fertile women must be using effective birth control. Effective contraception is defined as follows: o Injectable or implantable hormones; o Intrauterine device; o Trans-abdominal surgical sterilization; o Sterilization implant device; o Surgical sterilization of male partner; o Complete abstinence from sexual intercourse for two weeks before exposure to study medication and throughout the clinical study • Verbal and written consent to participate in the study • Documentation of the medicine status
|
|
E.4 | Principal exclusion criteria |
• Non-melanoma skin cancer, Mb. Bowen or keratoacanthoma in the treatment area • Previously treated with Ingenol Mebutate in the treatment area • Tattoos, moles, or other active dermatological condition in the treatment area • History of Psoriasis • Medication with a systemic immunosuppressive, cytotoxic, immune modulating or retinoid agent within the last 3 months • Use of topical applicants in the treated area that could interfere with the treatment or evaluation of the treatment the first 14 days, including commercially available day and night crèmes with retinoid agents • Pregnant and breastfeeding women • Patients that are considered incapable of complying with the protocol, i.e. patients suffering from dementia, alcoholism or psychiatric conditions
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Local skin reactions (LSR), clinical evaluation. Blinded clinical evaluation by a physician. The LSR Grading Scale is used to graduate Erythema 0-4, Flaking/Scaling 0-4, Crusting 0-4, Swelling 0-4, Vesiculation/Pustulation 0-4, Erosion/Ulceration 0-4. The scores are added for each patient, giving a maximum of 24 and a minimum of 0.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At day 1, 4, 8, 15 and 57 after treatment with Picato® |
|
E.5.2 | Secondary end point(s) |
1. Efficacy, day 15 and 57. a. Number of cleared AK's b. Complete clearance of the AK's in the field c. Partial clearance, >75% reduction in number of the AK's in the field d. Median reduction in the number of cleared AK's in the field e. New AKs All efficacy measures will be clinically evaluated by a blinded Dermatologist. The initial template is used to evaluate clearance of every original lesion. If not cleared, the grade of the remaining lesion is registered. 2. Photographic documentation of LSR and treatment effect, day 1, 4, 8, 15 and 57. At baseline and follow-up visits, LSR and clinical treatment effects will be photographically documented. 3. Reflectance at day 1,4,8,15 and 57 (Optimizer) The Optimizer is used to evaluate reflectance including Pigment protection factor, Pigmentation, Erythema, Green reflection and red reflection. The measures are aimed at the background skin in the center area and repeated three times, the median value is used. 4. Delayed side effects at day 15 and 57. Blinded clinical evaluation by a dermatologist. All treatment areas will be evaluated for hypopigmentation (0-3), hyperpigmentation (0-3) and scarring (0-2). 5. Patient satisfaction at day 15 and 57. The treating physician will ask the patient which one of the two treatments that was most satisfactory. 6. Pain and prutitus day 1-15 The patient will be asked to daily score LSR, pain and prutitus associated with the treatments in a patient diary. LSR are evaluated as "worse", "unchanged" or "better" compared to the day before. Every day the patient is asked if LSR are back to baseline. Pain is evaluated using a visual analog scale 0-10 and pruritus, 1-4.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | |